NASDAQ:AURA • US05153U1079
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AURA BIOSCIENCES INC (AURA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-26 | Evercore ISI Group | Reiterate | Outperform |
| 2025-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-23 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-03-26 | Citizens Capital Markets | Maintains | Market Outperform -> Market Outperform |
| 2025-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-18 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-10-18 | BTIG | Maintains | Buy -> Buy |
| 2024-10-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-13 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-09-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-28 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-07-25 | HC Wainwright & Co. | Initiate | Buy |
| 2023-12-08 | BTIG | Maintains | Buy -> Buy |
| 2023-11-10 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-07-27 | ScotiaBank | Initiate | Sector Outperform |
| 2023-03-16 | JMP Securities | Maintains | Outperform |
| 2022-11-11 | JMP Securities | Maintains | Market Outperform |
| 2022-07-19 | JMP Securities | Initiate | Market Outperform |
| 2021-11-23 | BTIG | Initiate | Buy |
| 2021-11-23 | SVB Leerink | Initiate | Outperform |
| 2021-11-23 | Cowen & Co. | Initiate | Outperform |
| 2021-11-23 | Evercore ISI Group | Initiate | Outperform |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 166.66% | N/A 186.07% | N/A 131.32% | N/A 110.25% | N/A 60.36% | |||||||
| EBITDA YoY % growth | -23.63M | -21.38M 9.52% | -34.42M -60.99% | -59.12M -71.76% | -83.696M -41.57% | -94.893M -13.38% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -24.14M | -22.21M 8.00% | -35.25M -58.71% | -60.3M -71.06% | -84.991M -40.95% | -96.116M -13.09% | N/A -23.61% | N/A -14.58% | N/A -8.09% | N/A 9.96% | N/A 34.71% | N/A 63.77% | N/A 260.14% | N/A 210.25% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -1.99 55.76% | -1.98 0.50% | -1.75 11.62% | N/A -14.24% | N/A 5.22% | N/A -0.32% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.44 19.70% | -0.46 3.06% | -0.45 -12.54% | -0.46 10.95% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -31.087M -7.07% | -32.139M -12.32% | -33.234M -19.09% | -34.342M -10.56% |
All data in USD
12 analysts have analysed AURA and the average price target is 18.87 USD. This implies a price increase of 188.09% is expected in the next year compared to the current price of 6.55.
AURA BIOSCIENCES INC (AURA) will report earnings on 2026-03-31, after the market close.
The consensus EPS estimate for the next earnings of AURA BIOSCIENCES INC (AURA) is -0.44 USD and the consensus revenue estimate is 0 USD.
The consensus rating for AURA BIOSCIENCES INC (AURA) is 83.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.